Synergistic effect of polymorphisms of paraoxonase gene cluster and arsenic exposure on electrocardiogram abnormality

Toxicology and Applied Pharmacology

Volumn 239, Issue 2, 2009, Pages 178-183

  Liao, Ya Tang ^a,b   Li, Wan Fen ^a   Chen, Chien Jen ^b,c   Prineas, Ronald J ^d   Chen, Wei J ^b   Zhang, Zhu Ming ^d   Sun, Chien Wen ^a   Wang, Shu Li ^a,e  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d Department of Epidemiology and Prevention   (United States)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Arsenic; Arsenic methyltransferase; Drinking water; Electrocardiogram; Glutathione S transferases omega; Ischemic heart disease; Paraoxonase

Indexed keywords

ARSENIC; ARSENIC METHYLTRANSFERASE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; DRINKING WATER; GLUTATHIONE TRANSFERASE; METHYLTRANSFERASE; TAP WATER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ECG ABNORMALITY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXON; FEMALE; GENE CLUSTER; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ARSENIC POISONING; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; ENVIRONMENTAL EXPOSURE; FEMALE; HAPLOTYPES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TAIWAN; WATER POLLUTANTS, CHEMICAL;

EID: 68949182924     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.12.017     Document Type: Article

References (36)

1. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
2. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., and Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101 (2000) 2510-2517
3. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., and Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
4. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., and La Du B.N. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 (2000) 1335-1342
5. Blackwell R.Q. Estimation total arsenic ingested by residents in the endemic blackfoot area. J. Formosan. Med. Assoc. 60 (1961) 1143-1144
6. Chen W.Y., and Chen K.P. Study on arsenic artesian well water and blackfoot disease progress. In Taichung, Taiwan: Taiwan Provincial Institute of Environmental Sanitation (1975), Taiwan Provincial Institute of Environmental Sanitation, Taichung, Taiwan
7. Chen C.J., and Lin L.J. Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In: Nriagu J.O. (Ed). Progress in Arsenic in the Environment, Part II (1994), Human Health and Ecosystem Effects, Wiley, New York
8. Chen K.P., Wu T.C., and Wu T.C. Epidemiologic studies on blackfoot disease in Taiwan. 3. Physicochemical characteristics of drinking water in endemic blackfoot disease areas. Memoirs of College of Medicine (National Taiwan University) 8 (1962) 115-129
9. Chen C.J., Chuang Y.C., Lin T.M., and Wu H.Y. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 45 (1985) 5895-5899
10. Chen C.J., Hsueh Y.M., Lai M.S., Shyu M.P., Chen S.Y., Wu M.M., Kuo T.L., and Tai T.Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25 (1995) 53-60
11. Chung J.S., Kalman D.A., Moore L.E., Kosnett M.J., Arroyo A.P., Beeris M., Mazumder D.N., Hernandez A.L., and Smith A.H. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ. Health Perspect. 110 (2002) 729-733
12. Department of Health, Executive Yuan (Taiwan) R. O. C. (2005). Health and Vital statistics-Vital Statistics.
13. Furlong C.E., Cole T.B., Jarvik G.P., and Costa L.G. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3 (2002) 341-348
14. Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., and Furlong C.E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2441-2447
15. Kuo, T. L. (1964). Arsenic Content of Artesian Well Water in Endemic Area of Chronic Arsenic Poisoning In Institute of Pathology, pp. 7-13. National Taiwan University.
16. Lin S., Shi Q., Nix F.B., Styblo M., Beck M.A., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., and Thomas D.J. A novel S-adenosyl-l-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 277 (2002) 10795-10803
17. Loffredo C.A., Aposhian H.V., Cebrian M.E., Yamauchi H., and Silbergeld E.K. Variability in human metabolism of arsenic. Environ. Res. 92 (2003) 85-91
18. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286 (1991) 152-154
19. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., and Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
20. Navas-Acien A., Sharrett A.R., Silbergeld E.K., Schwartz B.S., Nachman K.E., Burke T.A., and Guallar E. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am. J. Epidemiol. 162 (2005) 1037-1049
21. NRC. Arsenic in Drinking Water (1999), National Academy Press, Washington, DC
22. Potter D.M. A permutation test for inference in logistic regression with small- and moderate-sized data sets. Stat. Med. 24 (2005) 693-708
23. Prineas, R. J., Crow, R. S., and Blackburn, H. (1982). The Minnesota Code Manual of Electrocardiographic Findings. (John Wright PSB Inc., Ed.). MA, Boston.
24. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
25. Smith A.H., Lopipero P.A., Bates M.N., and Steinmaus C.M. Public health. Arsenic epidemiology and drinking water standards. Science 296 (2002) 2145-2146
26. Tanaka-Kagawa T., Jinno H., Hasegawa T., Makino Y., Seko Y., Hanioka N., and Ando M. Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem. Biophys. Res. Commun. 301 (2003) 516-520
27. Townsend D., and Tew K. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3 (2003) 157-172
28. Tseng W.P. Blackfoot disease in Taiwan: a 30-year follow-up study. Angiology 40 (1989) 547-558
29. Tseng C.H., Chong C.K., Tseng C.P., Hsueh Y.M., Chiou H.Y., Tseng C.C., and Chen C.J. Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol. Lett. 137 (2003) 15-21
30. Vahter, M. (2000). Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 112-113, 209-217.
31. Wang C.H., Hsiao C.K., Chen C.L., Hsu L.I., Chiou H.Y., Chen S.Y., Hsueh Y.M., Wu M.M., and Chen C.J. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol. Appl. Pharmacol. 222 (2007) 315-326
32. Watanabe C., Inaoka T., Kadono T., Nagano M., Nakamura S., Ushijima K., Murayama N., Miyazaki K., and Ohtsuka R. Males in rural Bangladeshi communities are more susceptible to chronic arsenic poisoning than females: analyses based on urinary arsenic. Environ. Health Perspect. 109 (2001) 1265-1270
33. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., and Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891
34. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
35. World Medical Association (2000). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. In Bulletin of Medical Ethics pp. 8-11.
36. Wu H.Y., Chen K.P., Tseng W.P., and Hsu C.L. Epidemiologic studies on blackfoot disease: prevalence and incidence of the disease by age, sex, year, occupation, and geographic distribution. Memoirs of College of Medicine (National Taiwan University) 7 (1961) 1-18